Acknowledgement of Issuance of Series F-2 Convertible Preferred Stock by Guided Therapeutics, Inc. to Purchasers under Securities Purchase Agreement
Guided Therapeutics, Inc. notifies purchasers from its December 23, 2020 Securities Purchase Agreement that, due to high demand, they may receive Series F-2 Convertible Preferred Stock instead of Series F. Both series have identical rights and preferences. Purchasers are asked to confirm their acceptance of Series F-2 shares in place of Series F shares. This acknowledgement ensures that all parties agree to the substitution of the preferred stock series.
Exhibit 10.1
GUIDED THERAPEUTICS, INC.
5835 Peachtree Corners East, Suite B
Norcross, Georgia 30092
April __, 2021
Purchasers pursuant to Securities Purchase Agreement
Dated December 23, 2020
Re: Creation of Series F-2 Convertible Preferred Stock
Dear Purchaser:
As previously disclosed in the public filings of Guided Therapeutics, Inc. (the “Company”), the recent private placement pursuant to the Securities Purchase Agreement, dated December 23, 2020, was well received and oversubscribed. As such and in order to create the necessary preferred shares of the Company to meet the increased demand, the Company has filed a Certificate of Designation titled Series F-2 Convertible Preferred Stock (the “Series F-2”) which has the same rights and preferences as the Series F Convertible Preferred Stock (“Series F”). The purpose of this letter is to notify you that you may receive Series F-2 instead of Series F but, as stated above, the rights and preferences of each of the preferred stock is identical in every respect.
Please confirm your acceptance of the Series F-2 shares in lieu of the Series F shares.
Thank you.
Sincerely,
Guided Therapeutics, Inc.
By: __________________
Name:
Title:
Accepted and Confirmed:
Name of Purchaser:
Signature of Purchaser:
Name of Signatory:
Title of Signatory:
